Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Sarepta Therapeutics shares surged as the company resumed U.S. shipments of its gene therapy, Elevidys, for ambulatory Duchenne muscular dystrophy patients, a move mirrored by partner Roche internationally. This follows FDA clearance that a patient death was not related to the treatment, alleviating immediate concerns about Sarepta's liquidity and the therapy's potential market withdrawal, which had been heightened by prior shipment pauses and regulatory scrutiny. While shipments for non-ambulatory patients remain halted, analysts largely view the resumption as significantly reducing the risk of formal market withdrawal, though some caution persists regarding the therapy's reputation and future sales figures.

Analysis

Sarepta Therapeutics (SRPT) experienced a significant share price rebound, surging as much as 32% to $18.35, after announcing the resumption of U.S. shipments for its gene therapy, Elevidys, to ambulatory patients. This move, mirrored by partner Roche for international markets, directly addresses and alleviates acute investor concerns regarding the company's liquidity and the potential for a complete market withdrawal of its largest revenue generator. The catalyst was a U.S. FDA determination that a patient death was unrelated to the treatment, which analysts like William Blair's Sami Corwin see as virtually eliminating the formal withdrawal risk. This development is critical for Sarepta's financial stability, enabling it to meet near-term payments to partners such as Arrowhead and maintain access to debt facilities. However, a material risk overhang remains, as shipments to non-ambulatory patients are still halted following earlier patient deaths. Consequently, some analysts remain cautious, highlighting the need to monitor future sales data to assess the impact of reputational damage on the therapy's commercial trajectory before fully discounting liquidity risks.

Key Decisions for Investors

• The FDA's clearance and partial resumption of Elevidys shipments represent a significant de-risking event, likely removing the primary bear-case scenario of a complete product withdrawal and addressing immediate balance sheet concerns.
• Investors should closely monitor upcoming sales figures for Elevidys to gauge the therapy's commercial traction and assess whether recent negative headlines have materially damaged its reputation and adoption rate among physicians and patients.
• The continued halt on shipments for non-ambulatory patients remains a key uncertainty, and any further adverse regulatory developments in this segment could reintroduce significant volatility to the stock.